ROCKVILLE, Md., May 11, 2016 /PRNewswire/ -- Synthetic Biologics,
Inc. (NYSE MKT: SYN), a clinical stage company focused on
developing therapeutics to protect the gut microbiome, announced
Isaac J. Bright, MD, has joined the
Company in the new position of Vice President, Corporate
Development. Dr. Bright will be responsible for strategic business
and corporate development activities to help maximize potential
partnering opportunities for the Company's two lead GI
microbiome-focused drug candidates: SYN-010, designed to reduce
methane production in the gut to treat an underlying cause of
irritable bowel syndrome with constipation (IBS-C), and SYN-004,
designed to prevent C. difficile infection (CDI), antibiotic
associated diarrhea (AAD) and the emergence of antibiotic resistant
organisms.
Dr. Bright is a life sciences and healthcare industry veteran
with 15 years of transactional and operational experience. Most
recently, he led the U.S. private equity investment practice as a
Partner at Merieux Development where he was responsible for
investment thesis development, company screening and comprehensive
due diligence for the healthcare and venture capital fund.
Previously, Dr. Bright served as Vice President, Corporate
Development and Diagnostics for QuantaLife, Inc. where he drove the
auction and trade sale process. His early career was devoted to
drug-device combination therapy programs at Medtronic, Inc.
"Isaac's perspective on GI microbiome-focused therapy
development is derived from his unique breadth of experience across
multiple classes of therapeutics in the life science and medical
device sectors," said Jeffrey Riley,
President and Chief Executive Officer of Synthetic Biologics. "As
we enhance our current partnering efforts, Isaac is expected to be
a strategic advocate for collaborative progress of our Phase 2 GI
microbiome-focused programs, and a strong leader as we continue to
explore opportunities with complementary industry
participants."
Dr. Bright is a Stanford University
Medical School-trained physician, and earned a BA degree in
Biochemistry from Pepperdine
University. He was a Howard E. Mitchell Fellow at the
Wharton School at University of
Pennsylvania where he earned an MBA. Dr. Bright has authored
several peer-reviewed papers and abstracts, serves on the Board of
Directors for ImaginAb, Inc. and is a Board Observer at Twist
Biosciences.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage
company developing therapeutics to protect the gut microbiome while
targeting pathogen-specific diseases. The Company's lead candidates
in Phase 2 development are: (1) SYN-010 which is intended to reduce
the impact of methane producing organisms in the gut microbiome to
treat an underlying cause of irritable bowel syndrome with
constipation (IBS-C), and (2) SYN-004 which is designed to protect
the gut microbiome from the effects of certain commonly used
intravenous (IV) antibiotics for the prevention of C.
difficile infection and antibiotic-associated diarrhea (AAD).
In collaboration with Intrexon Corporation, the Company is also
developing preclinical stage monoclonal antibody therapies for the
prevention and treatment of pertussis and novel discovery stage
biotherapeutics for the treatment of phenylketonuria (PKU). For
more information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 In
some cases forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions, and include statements
regarding the expected contribution and leadership of Dr. Bright in
exploring partnership opportunities, Synthetic Biologics' continued
exploration of partnership opportunities with complementary
industry participants and the potential benefits of SYN-004 and
SYN-010. These forward-looking statements are based management's
expectations and assumptions as of the date of this press release
and are subject to a number of risks and uncertainties, many of
which are difficult to predict that could cause actual results to
differ materially from current expectations and assumptions
from those set forth or implied by any forward-looking
statements. Important factors that could cause actual
results to differ materially from current expectations include,
among others, the ability of Dr. Bright to develop partnership
opportunities with complementary industry participants, a failure
to receive the necessary regulatory approvals for commercialization
of Synthetic Biologics' therapeutics, a failure of Synthetic
Biologics' clinical trials, and those conducted by investigators,
for SYN-004 and SYN-010 to be commenced or completed on time or to
achieve desired results and benefits, a failure of Synthetic
Biologics' clinical trials to continue enrollment as expected or
receive anticipated funding, a failure of Synthetic Biologics to
successfully develop, market or sell its products, Synthetic
Biologics' inability to maintain its material licensing agreements,
or a failure by Synthetic Biologics or its strategic partners to
successfully commercialize products and other factors described in
Synthetic Biologics' Annual Report on Form 10-K for the year ended
December 31, 2015 and its other
filings with the SEC, including subsequent periodic reports on
Forms 10-Q and 8-K. The information in this release is provided
only as of the date of this release, and Synthetic Biologics
undertakes no obligation to update any forward-looking statements
contained in this release on account of new information, future
events, or otherwise, except as required by law.
Logo - http://photos.prnewswire.com/prnh/20160105/319502LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/isaac-j-bright-md-joins-synthetic-biologics-as-vice-president-corporate-development-300266474.html
SOURCE Synthetic Biologics, Inc.